Welcome to our dedicated page for APIMEDS PHARMACEUTICALS US news (Ticker: APUS), a resource for investors and traders seeking the latest updates and insights on APIMEDS PHARMACEUTICALS US stock.
Apimeds Pharmaceuticals US, Inc. develops non-opioid, biologic-based therapies for pain management as a clinical-stage biopharmaceutical company. Company news centers on Apitox, also referenced as LT-100, a pure honeybee venom biologic candidate for signs and symptoms of osteoarthritis, with historical approval in South Korea under the Apitoxin name.
Recurring updates also cover U.S. regulatory interactions, clinical-development planning, material agreements, shareholder voting and governance matters, capital-structure disclosures, and operating results. Apimeds has also announced ai² Futures Lab collaborations tied to evaluation of early-stage pharmaceutical assets and biopharma business development projects.
Apimeds Pharmaceuticals (NYSE American: APUS) has launched its ai² Future Labs program in partnership with The University of Alabama's Culverhouse College of Business. The initiative connects university students with real-world biopharmaceutical strategy and business development projects, focusing on identifying and evaluating abandoned drug development projects with potential.
Through this program, students will gain hands-on experience in market analysis, FDA regulations, clinical development, and commercialization planning. Top-performing teams will be eligible for paid internships or consulting opportunities with Apimeds. The partnership marks the first of several planned academic collaborations under the ai² innovation platform.
Apimeds (NYSE American: APUS), a clinical-stage biopharmaceutical company developing Apitox, a bee venom-based therapeutic, has announced two significant leadership appointments. Dr. Susan Kramer joins as Senior Vice President of Development, bringing over 30 years of biopharmaceutical experience, including 18 years at Genentech. Brian Peters has been appointed as Head of the company's proprietary ai²™ division.
Dr. Kramer, who previously served as Executive VP of Development at Concentric Analgesics, will oversee all product development activities. Peters, former Chief Strategy & Insights Officer at Heller Agency, will lead the strategy and launch of the ai²™ platform. Both appointments follow Apimeds' recent IPO and aim to strengthen the company's operational leadership.
Apimeds Pharmaceuticals US (NYSE American: APUS) has successfully completed its Initial Public Offering (IPO), raising $13.5 million in gross proceeds through the sale of 3,375,000 common stock shares at $4.00 per share. The company's shares began trading on NYSE American under the symbol "APUS" on May 9, 2025.
The clinical-stage biopharmaceutical company is developing Apitox, an intradermally administered bee venom-based toxin with potential therapeutic applications. The IPO proceeds will fund a Phase III clinical trial in knee osteoarthritis, initiate corporate sponsorship studies in multiple sclerosis, support product manufacturing, and address working capital needs.
D. Boral Capital served as the sole book-running manager, with underwriters receiving a 45-day option to purchase up to 506,250 additional shares and warrants for up to 168,750 shares.